## A: Agilent Technologies, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -4.8% below STRENGTH zone (4.0-10.0%); PEG 2.23 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($129.44)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 6, Bearish: 0)

**1. Agilent Technologies opens India Refurbishment Center to advance sustainable science and affordable innovation**
- Source: Pharmabiz.com | 20251217T100731 | Bullish | Relevance: 100%
- Agilent Technologies has opened its India Refurbishment Center in Manesar, Haryana, aiming to provide Certified Pre-Owned (CPO) instruments to support sustainable science and affordability in India. This center, along with a new India Education Center, will offer high-quality, cost-effective solutions, advanced training, and flexible financing options to laboratories, reinforcing Agilent's commitment to the Indian market. The initiative also promotes circular economy principles by offering trade-in and buyback programs for used instruments.

**2. Agilent Technologies opens India Refurbishment Centre in Manesar**
- Source: BioSpectrum India | 20251217T091322 | Bullish | Relevance: 100%
- Agilent Technologies has inaugurated its India Refurbishment Centre in Manesar, Haryana, enhancing its commitment to sustainable science and affordability in India. This center will provide Certified Pre-Owned instruments and hands-on training through an associated India Education Centre. The initiative aims to support laboratories with cost-effective, high-quality solutions and integrate sustainable practices into the market.

**3. Agilent to Present at the 44th Annual J.P. Morgan Healthcare Conference**
- Source: Markets Financial Content | 20251216T130818 | Neutral | Relevance: 100%
- Agilent Technologies Inc. announced that CEO Padraig McDonnell and CFO Adam Elinoff will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, from 9 to 9:40 a.m. PST. A live audio webcast and replay will be available on Agilentâ€™s Investor Relations website. Agilent is a global leader in analytical and clinical laboratory technologies, with $6.95 billion in revenue in fiscal year 2025.

**4. Agilent Technologies (A) price target increased by 10.53% to 170.51**
- Source: MSN | 20251216T030736 | Bullish | Relevance: 100%
- The price target for Agilent Technologies (A) has been increased by 10.53%, bringing it to $170.51. This adjustment reflects new analyst projections for the company's valuation.

**5. Aaron Wealth Advisors LLC Increases Position in Agilent Technologies, Inc. $A**
- Source: MarketBeat | 20251217T080722 | Somewhat-Bullish | Relevance: 100%
- Aaron Wealth Advisors LLC significantly boosted its stake in Agilent Technologies, Inc. (NYSE:A) by 322.2% in Q3, now holding 9,672 shares valued at $1.24 million. Despite insider selling activity, including sales by CEO Padraig McDonnell and VP Rodney Gonsalves, analysts maintain a "Moderate Buy" rating for Agilent with an average target price of $161.77. The company recently reported strong Q3 earnings, beating estimates and raising its quarterly dividend.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 7, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-15 | Barclays | $165 | $165 | 0% |
| 2025-12-09 | Goldman Sachs | $170 | $0 | 0% |
| 2025-12-02 | Morgan Stanley | $180 | $0 | 0% |
| 2025-11-25 | Citigroup | $185 | $165 | +12% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-15 | Barclays | up | Overweight |
| 2025-12-09 | Goldman Sachs | init | Buy |
| 2025-12-02 | Morgan Stanley | init | Overweight |
| 2025-11-25 | Citigroup | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 10 ($1.37M) |
| Sells | 18 ($1.60M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 44.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 12.0% (+0.1%)
- Blackrock Inc.: 9.2% (+1.0%)
- Massachusetts Financ: 4.4% (-6.0%)
- State Street Corpora: 4.4% (-0.1%)
- Wellington Managemen: 3.3% (+4.8%)

### Key Risks

1. Near-term weakness: 5.9% below SMA50 despite long-term uptrend.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 7 raises (avg +12%) could attract flows.
- AI/machine learning initiatives could drive multiple expansion if executed.

### Fundamentals

PEG ratio 2.23 elevated, pricing in significant growth expectations. Forward P/E 20.8x stretched relative to 10% growth. Quality metrics strong (ROE 21%, margin 19%). Analyst sentiment positive (7 raises, avg +12%). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $38.7B |
| Beta | 1.27 |
| 52W Range | $96.43 - $160.27 |
| Short Interest | 1.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.23 |
| Forward P/E | 20.8 |
| Current P/E | 23.0 |
| YoY Growth | 10.3% |
| EPS Direction | STABLE |

### Technicals

MRS_20 improving modestly (+0.6% over 5 days). Below STRENGTH zone by 8.8pp (needs >4.0% for momentum thesis). AM_20 at -6.6% indicates price below own 20MA trend. Underperforming sector by 6.4pp, stock-specific weakness. Long-term uptrend intact (above SMA200 at 1.10x) but short-term weakness (below SMA20). MACD histogram bearish (-1.43), momentum weakening. OFD pattern: -MTN (Decline).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -4.76% (CS: 10) | Weak |
| RSI_14 | 34.9 | Neutral |
| MACD Histogram | -1.43 | Bearish |
| vs SMA20 | 0.934x | Below |
| vs SMA50 | 0.941x | Below |
| vs SMA200 | 1.099x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $136.68
- **Stop Loss:** $129.44 (5.3% risk)
- **Target:** $143.92 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 149
- **Position Value:** $20,365.32
- **Portfolio %:** 20.37%
- **Risk Dollars:** $1,080.00
- **Risk Per Trade:** 1.08%
- **Modifiers:** L1 90% | L2 120% | Combined 1.08x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | RISK_OFF (HIGH) | 0.90x |
| L2 Sector | TREND (Zone A) | 1.20x |

*RISK_OFF regime with deteriorating conditions. VIX rising to 17.6 (+11.7% over 5 days) signals increasing anxiety, while narrow breadth at 52.6% indicates selective participation. AI infrastructure cost concerns are pressuring tech leadership, creating sector rotation challenges in a late-cycle environment.*

### Earnings

**Next:** 2026-02-25 (Est: $1.37)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q4 | $1.58 | $1.59 | +0.4% |
| 2025Q3 | $1.37 | $1.37 | +0.2% |
| 2025Q2 | $1.26 | $1.31 | +3.6% |
| 2025Q1 | $1.27 | $1.31 | +3.0% |

---
*RULE-based L3 | 2026-01-07 01:41 | MRS_20*